LianBio (LIAN) Competitors

20.1% of Greenland Mines Ltd. Common Stock shares are owned by institutional investors. Comparatively, 74.8% of LianBio shares are owned by institutional investors. 9.9% of Greenland Mines Ltd. Common Stock shares are owned by company insiders. Comparatively, 7.6% of LianBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Greenland Mines Ltd. Common Stock has a beta of 7.61, suggesting that its stock price is 661% more volatile than the S&P 500. Comparatively, LianBio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500.

LianBio's return on equity of -33.17% beat Greenland Mines Ltd. Common Stock's return on equity.

In the previous week, Greenland Mines Ltd. Common Stock had 3 more articles in the media than LianBio. MarketBeat recorded 3 mentions for Greenland Mines Ltd. Common Stock and 0 mentions for LianBio. LianBio's average media sentiment score of 0.00 beat Greenland Mines Ltd. Common Stock's score of 0.00 indicating that LianBio is being referred to more favorably in the news media.

Greenland Mines Ltd. Common Stock is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

74.8% of LianBio shares are owned by institutional investors. 17.8% of Metagenomi shares are owned by company insiders. Comparatively, 7.6% of LianBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Metagenomi has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, LianBio has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500.

LianBio has a net margin of 0.00% compared to Metagenomi's net margin of -348.54%. LianBio's return on equity of -33.17% beat Metagenomi's return on equity.

Metagenomi presently has a consensus target price of $10.00, indicating a potential upside of 609.22%. Given Metagenomi's stronger consensus rating and higher probable upside, equities research analysts plainly believe Metagenomi is more favorable than LianBio.

In the previous week, Metagenomi had 1 more articles in the media than LianBio. MarketBeat recorded 1 mentions for Metagenomi and 0 mentions for LianBio. Metagenomi's average media sentiment score of 0.00 equaled LianBio'saverage media sentiment score.

Metagenomi has higher revenue and earnings than LianBio. Metagenomi is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

74.8% of LianBio shares are owned by institutional investors. 7.6% of LianBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

LianBio's return on equity of -33.17% beat Telomir Pharmaceuticals' return on equity.

Telomir Pharmaceuticals has a beta of -0.21, suggesting that its share price is 121% less volatile than the S&P 500. Comparatively, LianBio has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500.

In the previous week, Telomir Pharmaceuticals had 1 more articles in the media than LianBio. MarketBeat recorded 1 mentions for Telomir Pharmaceuticals and 0 mentions for LianBio. Telomir Pharmaceuticals' average media sentiment score of 0.00 equaled LianBio'saverage media sentiment score.

Rallybio has higher revenue and earnings than LianBio. Rallybio is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

74.8% of LianBio shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 7.6% of LianBio shares are held by insiders. Comparatively, 10.3% of Rallybio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

LianBio has a net margin of 0.00% compared to Rallybio's net margin of -1,046.39%. LianBio's return on equity of -33.17% beat Rallybio's return on equity.

LianBio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.1, suggesting that its stock price is 210% less volatile than the S&P 500.

In the previous week, Rallybio had 2 more articles in the media than LianBio. MarketBeat recorded 2 mentions for Rallybio and 0 mentions for LianBio. Rallybio's average media sentiment score of 1.05 beat LianBio's score of 0.00 indicating that Rallybio is being referred to more favorably in the news media.